Dr. Jef Vangenechten, Group Chief Executive Officer
Dr. Jef Vangenechten is also currently CEO of DIAsource Immunoassays. Previously he served as Executive Vice President Commercial Operations at BioSource International and as CEO of BioSource Europe (Diagnostic and Life Sciences). He led the Management Buy-Out of BioSource Europe from Invitrogen in February 2007 and has since then held the position of CEO of the resulting entity, DIAsource ImmunoAssays.
Peter Harding-Smith, Group Chief Financial Officer
Mr Harding-Smith brings a wealth of financial, governance and company secretarial experience to Anteo. He is a Chartered Accountant, a Fellow of the Governance Institute of Australia and has over 10 years' experience in ASX listed companies as Chief Financial Officer and Company Secretary.
N.Joe Maeji, Chief Scientific Officer
Dr Joe Maeji has more than 20 years’ experience managing successful R&D projects in the biotechnology and life science industries. His focus has been on the commercialisation of products and technologies at the interface of chemistry and biology. He has significant experience in successfully securing funding for the development of new technologies, as well as in creating and securing extensive IP portfolios. Joe was a co-founder and founding CEO of the Bio-Layer Pty Ltd, company that became Anteo Technologies.
Rachel de las Heras, Head of Commercial Development
Dr Rachel de las Heras has a solid track record of successfully executing projects in both commercial and research settings with over 15 years’ experience in providing leadership of cross-functional teams. Rachel has demonstrated experience in creating novel intellectual property associated with new product development and translating new technologies through the development cycle into products for market entry at both Panbio Ltd and Cellestis Ltd.
Charlie Huang, Head of Research and Development
Dr Charlie Huang has more than 20 years’ experience in multi-discipline research and development. He has demonstrated scientific expertise in protein engineering, molecular biology, enzyme kinetics, drug discovery, bio-conjugation, bio-separation, immunoassay development, rapid and point of care diagnostics and nano-biotechnology. He also has significant commercial expertise in project management, technology analysis, licensing and intellectual proprieties management.
Michael Carroll, Head of Production and Technical Development
Michael has over 10 years experience in IVD/MD manufacture, having worked for local and multinational companies, both in Australia and in Asia. He brings a strong commitment to excellence and innovation, a pragmatic approach to problem-solving, and an understanding of the complexities of commercial scale in a resource-constrained environment. Michael is extensively experienced in GMP, and putting in place ISO 9001/13485 quality management systems that reflect the needs and vision of the organisation.